What are the chances we presently have of carrying a cardiovascular disease at some point in our lives?

Original title: Lifetime Risk and Years Lived Free of Total Cardiovascular Disease Reference: John T. Wilkins et al. JAMA. 2012; 308(17):1795-1801.

This study analyzed more than 120,000 patients in the cohorts of large community studies, such as the Framingham, who did not have cardiovascular disease at the time of inclusion 

Considering all the age subgroups, only between 1.7% and 7.9% were within the optimal range of risk factors, (BP <120/80 mmHg, total cholesterol

In contrast, more than 55% of the population had one or two risk factors analyzed whatever their age. With this data it was possible to calculate, for example, that a 45 year-old man with no history has a 60.3% risk of contracting a cardiovascular disease at some point in his life.

For a woman of the same age the risk factor is 55.6%. In a middle age, a person with optimal risk control factors has an estimated 14 more years of free cardiovascular disease than someone of the same age with 2 risk factors. However, despite the likelihood of optimal control of risk, the odds of contracting an illness are still above 30%.

Editorial Comment: 

This study shows the enormous prevalence of cardiovascular disease and that this will continue to rise beyond the level that medical treatment can manage. Dealing with this huge number of patients is not only going to be a challenge for us in the catheterization laboratory but also an enormous public health problem.

SOLACI.ORG

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...